Next Article in Journal
HIV-1 Virological Synapse: Live Imaging of Transmission
Next Article in Special Issue
Targeting HCV Entry For Development of Therapeutics
Previous Article in Journal / Special Issue
The Hepatitis C Virus Nonstructural Protein 2 (NS2): An Up-and-Coming Antiviral Drug Target
Viruses 2010, 2(8), 1647-1665; doi:10.3390/v2081647

Possibilities for RNA Interference in Developing Hepatitis C Virus Therapeutics

Department of Microbiology, The University of Chicago, Chicago, IL 60637, USA
* Author to whom correspondence should be addressed.
Received: 6 July 2010 / Revised: 4 August 2010 / Accepted: 4 August 2010 / Published: 6 August 2010
(This article belongs to the Special Issue Antivirals Against Hepatitis C Virus)
View Full-Text   |   Download PDF [211 KB, uploaded 12 May 2015]   |   Browse Figure


The discovery and characterization of the RNA interference (RNAi) pathway has been one of the most important scientific developments of the last 12 years. RNAi is a cellular pathway wherein small RNAs control the expression of genes by either degrading homologous RNAs or preventing the translation of RNAs with partial homology. It has impacted basic biology on two major fronts. The first is the discovery of microRNAs (miRNAs), which regulate almost every cellular process and are required for some viral infections, including hepatitis C virus (HCV). The second front is the use of small interfering RNAs (siRNAs) as the first robust tool for mammalian cellular genetics. This has led to the identification of hundreds of cellular genes that are important for HCV infection. There is now a major push to adapt RNAi technology to the clinic. In this review, we explore the impact of RNAi in understanding HCV biology, the progress in design of RNAi-based therapeutics for HCV, and remaining obstacles.
Keywords: RNA interference; hepatitis C virus; siRNA therapy RNA interference; hepatitis C virus; siRNA therapy
This is an open access article distributed under the Creative Commons Attribution License (CC BY) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
EndNote |
MDPI and ACS Style

Berger, K.L.; Randall, G. Possibilities for RNA Interference in Developing Hepatitis C Virus Therapeutics. Viruses 2010, 2, 1647-1665.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here


[Return to top]
Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert